Who Buys Sunitinib from India — 188 Importers Behind a $63.6M Market
India's sunitinib import market is served by 188 active buyers who collectively imported $63.6M across 607 shipments. TARO PHARMACEUTICALS INC., (CANADA) leads with a 45.0% market share, followed by SUN PHARMACEUTICAL INDUSTRIES,INC. and NORTHSTAR DISTRIBUTION CENTER 8912. The top 5 buyers together control 68.3% of total import value, reflecting a concentrated buyer landscape.
Sunitinib buyer data — 188 importers · $63.6M market · 607 shipmentsTransData Nexus · Indian Customs Data
Top Sunitinib Importers — Ranked by Import Value
TARO PHARMACEUTICALS INC., (CANADA) is the leading sunitinib importer from India, holding a 45.0% share of the $63.6M market across 607 shipments from 188 buyers. The top 5 buyers — TARO PHARMACEUTICALS INC., (CANADA), SUN PHARMACEUTICAL INDUSTRIES,INC. (UNITED STATES), NORTHSTAR DISTRIBUTION CENTER 8912 (UNITED STATES), SUN PHARMACEUTICAL INDUSTRIES INC (UNITED STATES), SUN PHARMA CANADA INC (CANADA) — collectively control 68.3% of total import value.
Top Sunitinib Buyers & Importers
Ranked by import value · 188 active buyers · Indian Customs (DGFT) data
Mar 2026
Top Sunitinib Buyers & Importers — Ranked by Import Value. 188 active buyers with import value, shipments, country and supplier data compiled from Indian Customs records by TransData Nexus.
Which companies are buying Sunitinib — and from which countries?
Flow of Sunitinib exports from India: each country's share and the named importers behind the numbers
Sunitinib — Buyer Countries to Key Importers
Trade flow: top importing countries → named buyer companies
Top 5 importing countries account for 94.9% of global Sunitinib imports — led by Canada (50.5%) with a total trade value of $63.6M across 607 shipments from India.
Market Analysis: Top Importing Countries & Their Importers
1Canada
Canada emerges as the first largest importing country, achieving a total trade value of $32.1M through 36 shipments. This represents a market share of 50.5% of the total market activity, demonstrating their significant presence in the industry.
Top Importers: Canada has a diverse importer base, with their top importers including:
• TARO PHARMACEUTICALS INC., - $28.6M (89.1% of country's total business)
• SUN PHARMA CANADA INC - $1.5M (4.6% of country's total business)
• SUN PHARMA ANZ PTY LTD - $1.1M (3.4% of country's total business)
• TARO PHARMACEUTICALS INC. - $983.8K (3.1% of country's total business)
• TARO PHARMACEUTICALS USA INC., - $569.9K (1.8% of country's total business)
• Rest of Canada's importers - $-607.1K (-1.9% of country's total business)
Key Insight: Canada demonstrates strong market positioning with an average shipment value of $892.1K, indicating premium pricing strategy compared to the market average of $104.8K.
Canada is a key market for Sunitinib imports, representing 50.5% of total trade value.
The importation of Sunitinib from India involves various buyer segments, each with distinct purchasing behaviors:
Pharmaceutical Companies: Entities like TARO PHARMACEUTICALS INC. (Canada) and SUN PHARMACEUTICAL INDUSTRIES INC. (United States) are prominent buyers, accounting for significant portions of the total import value. These companies typically procure large quantities to support their manufacturing and distribution operations, ensuring a steady supply chain for their markets.
Distributors: Organizations such as NORTHSTAR DISTRIBUTION CENTER 8912 (United States) and YUSEN LOGISTICS BENELUX BELGIUM (Belgium) function as intermediaries, purchasing Sunitinib in bulk and supplying it to various healthcare providers. Their buying patterns are influenced by market demand and inventory management strategies.
Regional Subsidiaries: Entities like SUN PHARMA CANADA INC. (Canada) and SUN PHARMA ANZ PTY LTD (Canada) represent regional arms of larger pharmaceutical companies. They import Sunitinib to cater to specific regional markets, aligning their procurement with local demand and regulatory requirements.
Contract Manufacturers: Companies such as RANBAXY (MALAYSIA) SDN BHD (Malaysia) may act as contract manufacturers, importing Sunitinib for formulation and packaging before distribution. Their procurement is typically project-based, depending on contractual agreements and production schedules.
The top five importing countries have distinct regulatory frameworks for importing Sunitinib:
Canada:
Regulatory Authority: Health Canada.
Import Registration Process: Importers must obtain a Drug Establishment License (DEL) and ensure the product complies with the Food and Drugs Act and Regulations. Exceptional importation may be permitted during drug shortages, as indicated in Health Canada's archived lists.
Estimated Timeline for Registration: The DEL application process can take several months, depending on the completeness of the submission and compliance with regulatory requirements.
Import Tariff/Duty for HS 30049099: Pharmaceutical products under HS code 30049099 are typically duty-free in Canada, but importers should verify current tariff schedules.
The demand for Sunitinib in importing countries is driven by several factors:
Disease Prevalence: Sunitinib is primarily used to treat certain types of cancer, including renal cell carcinoma and gastrointestinal stromal tumors. The prevalence of these cancers influences demand, with higher incidence rates leading to increased need for effective treatments.
Government Healthcare Programs: Many countries have national health programs that subsidize or fully cover the cost of essential medicines, including cancer treatments. For instance, China's National Reimbursement Drug List includes targeted therapies, impacting procurement patterns.
Universal Health Coverage Expansion: Efforts to expand universal health coverage increase access to essential medicines. Countries investing in healthcare infrastructure and coverage are likely to see a rise in demand for drugs like Sunitinib.
WHO Essential Medicines List Procurement: Inclusion of medicines in the WHO Essential Medicines List encourages countries to procure these drugs to meet public health needs. While Sunitinib's inclusion status should be verified, its recognition can drive procurement.
Common Questions — Sunitinib Buyers & Importers
Answers based on Indian Customs (DGFT) shipment records compiled by TransData Nexus
QWho is the largest sunitinib buyer importing from India?
Based on import volume and value, TARO PHARMACEUTICALS INC., (CANADA) leads with $28.6M in imports and a 45.0% market share — the highest of any single sunitinib importer. SUN PHARMACEUTICAL INDUSTRIES,INC. (UNITED STATES) and NORTHSTAR DISTRIBUTION CENTER 8912 (UNITED STATES) are the next largest buyers.
QHow many companies buy sunitinib from India?
There are 188 active sunitinib buyers importing from India, with a combined market of $63.6M across 607 shipments to 76 countries. The top 5 buyers hold 68.3% of total import value, while the remaining 183 buyers handle the other 31.7%.
QWhich countries import the most sunitinib from India?
The top importing countries for sunitinib from India are Canada (50.5%), United States (38.4%), Peru (2.5%), Belgium (1.9%), Australia (1.6%). These markets represent the largest demand centres for Indian pharmaceutical exports of sunitinib, with buyers ranging from government procurement agencies to private pharmaceutical distributors.
QWhat is the average import order value for sunitinib from India?
The average import transaction value for sunitinib from India is , with an average unit price of . Order sizes vary significantly based on buyer type — government tenders tend to be larger while private distributors place more frequent smaller orders.
The importation of Sunitinib from India involves various buyer segments, each with distinct purchasing behaviors:
Pharmaceutical Companies: Entities like TARO PHARMACEUTICALS INC. (Canada) and SUN PHARMACEUTICAL INDUSTRIES INC. (United States) are prominent buyers, accounting for significant portions of the total import value. These companies typically procure large quantities to support their manufacturing and distribution operations, ensuring a steady supply chain for their markets.
Distributors: Organizations such as NORTHSTAR DISTRIBUTION CENTER 8912 (United States) and YUSEN LOGISTICS BENELUX BELGIUM (Belgium) function as intermediaries, purchasing Sunitinib in bulk and supplying it to various healthcare providers. Their buying patterns are influenced by market demand and inventory management strategies.
Regional Subsidiaries: Entities like SUN PHARMA CANADA INC. (Canada) and SUN PHARMA ANZ PTY LTD (Canada) represent regional arms of larger pharmaceutical companies. They import Sunitinib to cater to specific regional markets, aligning their procurement with local demand and regulatory requirements.
Contract Manufacturers: Companies such as RANBAXY (MALAYSIA) SDN BHD (Malaysia) may act as contract manufacturers, importing Sunitinib for formulation and packaging before distribution. Their procurement is typically project-based, depending on contractual agreements and production schedules.
The top five importing countries have distinct regulatory frameworks for importing Sunitinib:
Canada:
Regulatory Authority: Health Canada.
Import Registration Process: Importers must obtain a Drug Establishment License (DEL) and ensure the product complies with the Food and Drugs Act and Regulations. Exceptional importation may be permitted during drug shortages, as indicated in Health Canada's archived lists.
Estimated Timeline for Registration: The DEL application process can take several months, depending on the completeness of the submission and compliance with regulatory requirements.
Import Tariff/Duty for HS 30049099: Pharmaceutical products under HS code 30049099 are typically duty-free in Canada, but importers should verify current tariff schedules.
The demand for Sunitinib in importing countries is driven by several factors:
Disease Prevalence: Sunitinib is primarily used to treat certain types of cancer, including renal cell carcinoma and gastrointestinal stromal tumors. The prevalence of these cancers influences demand, with higher incidence rates leading to increased need for effective treatments.
Government Healthcare Programs: Many countries have national health programs that subsidize or fully cover the cost of essential medicines, including cancer treatments. For instance, China's National Reimbursement Drug List includes targeted therapies, impacting procurement patterns.
Universal Health Coverage Expansion: Efforts to expand universal health coverage increase access to essential medicines. Countries investing in healthcare infrastructure and coverage are likely to see a rise in demand for drugs like Sunitinib.
WHO Essential Medicines List Procurement: Inclusion of medicines in the WHO Essential Medicines List encourages countries to procure these drugs to meet public health needs. While Sunitinib's inclusion status should be verified, its recognition can drive procurement.
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
2United States
United States emerges as the second largest importing country, achieving a total trade value of $24.4M through 60 shipments. This represents a market share of 38.4% of the total market activity, demonstrating their significant presence in the industry.
Top Importers: United States has a diverse importer base, with their top importers including:
• SUN PHARMACEUTICAL INDUSTRIES,INC. - $6.9M (28.4% of country's total business)
• NORTHSTAR DISTRIBUTION CENTER 8912 - $3.5M (14.4% of country's total business)
• SUN PHARMACEUTICAL INDUSTRIES INC - $2.9M (11.9% of country's total business)
Key Insight: United States demonstrates strong market positioning with an average shipment value of $406.8K, indicating premium pricing strategy compared to the market average of $104.8K.
United States is a key market for Sunitinib imports, representing 38.4% of total trade value.
Primary Market
Secondary Market
3Peru
Peru emerges as the third largest importing country, achieving a total trade value of $1.6M through 11 shipments. This represents a market share of 2.5% of the total market activity, demonstrating their significant presence in the industry.
Top Importers: Peru has a diverse importer base, with their top importers including:
• SUN PHARMACEUTICAL INDUSTRIES - $910.4K (56.8% of country's total business)
• MSN LABS PERU SAC - $279.9K (17.5% of country's total business)
Key Insight: Peru demonstrates strong market positioning with an average shipment value of $145.8K, indicating premium pricing strategy compared to the market average of $104.8K.
Peru is a key market for Sunitinib imports, representing 2.5% of total trade value.
Primary Market
Secondary Market
4Belgium
Belgium emerges as the fourth largest importing country, achieving a total trade value of $1.2M through 21 shipments. This represents a market share of 1.9% of the total market activity, demonstrating their significant presence in the industry.
Top Importers: Belgium has a diverse importer base, with their top importers including:
• YUSEN LOGISTICS BENELUX BELGIUM - $1.2M (100.0% of country's total business)
Key Insight: Belgium demonstrates strong market positioning with an average shipment value of $58.3K, indicating competitive pricing strategy compared to the market average of $104.8K.
Belgium is a key market for Sunitinib imports, representing 1.9% of total trade value.
Primary Market
Secondary Market
5Australia
Australia emerges as the fifth largest importing country, achieving a total trade value of $994.3K through 3 shipments. This represents a market share of 1.6% of the total market activity, demonstrating their significant presence in the industry.
Top Importers: Australia has a diverse importer base, with their top importers including:
• SUN PHARMA ANZ PTY LIMITED - $281.5K (28.3% of country's total business)
Key Insight: Australia demonstrates strong market positioning with an average shipment value of $331.4K, indicating premium pricing strategy compared to the market average of $104.8K.
Australia is a key market for Sunitinib imports, representing 1.6% of total trade value.
Primary Market
Secondary Market
Each segment's purchasing behavior reflects its role in the pharmaceutical supply chain, with factors like market demand, regulatory compliance, and strategic partnerships influencing order patterns.
TransData Nexus Research · Government and regulatory sourcesMar 2026
Regulatory Authority: U.S. Food and Drug Administration (FDA).
Import Registration Process: Importers must ensure Sunitinib is FDA-approved and comply with the Drug Supply Chain Security Act (DSCSA). The FDA's Safe Importation Action Plan outlines pathways for importing certain prescription drugs from Canada.
Estimated Timeline for Registration: Timelines vary based on the importation pathway; state-sponsored programs may require several months for approval.
Import Tariff/Duty for HS 30049099: Pharmaceutical products under this HS code are generally duty-free, but importers should confirm with U.S. Customs and Border Protection.
Peru:
Regulatory Authority: Dirección General de Medicamentos, Insumos y Drogas (DIGEMID).
Import Registration Process: Importers must register pharmaceutical products with DIGEMID, providing documentation on product quality, safety, and efficacy.
Estimated Timeline for Registration: The registration process can take approximately 6 to 12 months, depending on the complexity of the application.
Import Tariff/Duty for HS 30049099: Pharmaceutical imports may be subject to tariffs; importers should consult the latest tariff schedules from Peruvian customs authorities.
Belgium:
Regulatory Authority: Federal Agency for Medicines and Health Products (FAMHP).
Import Registration Process: Importers must obtain a marketing authorization from FAMHP, ensuring compliance with European Medicines Agency (EMA) standards.
Estimated Timeline for Registration: The process typically takes 7 to 12 months, depending on the completeness of the dossier and any additional information requests.
Import Tariff/Duty for HS 30049099: As an EU member, Belgium generally applies a 0% tariff on pharmaceutical products under this HS code, but importers should verify current rates.
Import Registration Process: Importers must register Sunitinib in the Australian Register of Therapeutic Goods (ARTG) and comply with TGA regulations.
Estimated Timeline for Registration: The registration process can take 12 to 18 months, depending on the quality of the submission and any additional data requirements.
Import Tariff/Duty for HS 30049099: Pharmaceutical products under this HS code are typically duty-free in Australia, but importers should confirm with the Australian Border Force.
TransData Nexus Research · Government and regulatory sourcesMar 2026
Tender-Based Purchasing: Many governments and large healthcare providers use tender systems to procure medicines, aiming for cost-effectiveness and supply security. This approach can lead to bulk purchasing and stable demand for Sunitinib.
With 188 buyers across 76 countries, the global market for Sunitinib reflects a broad and sustained demand, influenced by healthcare policies, disease burden, and procurement strategies.
TransData Nexus Research · Government and regulatory sourcesMar 2026
$104.8K
$164.27 per unit
Each segment's purchasing behavior reflects its role in the pharmaceutical supply chain, with factors like market demand, regulatory compliance, and strategic partnerships influencing order patterns.
TransData Nexus Research · Government and regulatory sourcesMar 2026
Regulatory Authority: U.S. Food and Drug Administration (FDA).
Import Registration Process: Importers must ensure Sunitinib is FDA-approved and comply with the Drug Supply Chain Security Act (DSCSA). The FDA's Safe Importation Action Plan outlines pathways for importing certain prescription drugs from Canada.
Estimated Timeline for Registration: Timelines vary based on the importation pathway; state-sponsored programs may require several months for approval.
Import Tariff/Duty for HS 30049099: Pharmaceutical products under this HS code are generally duty-free, but importers should confirm with U.S. Customs and Border Protection.
Peru:
Regulatory Authority: Dirección General de Medicamentos, Insumos y Drogas (DIGEMID).
Import Registration Process: Importers must register pharmaceutical products with DIGEMID, providing documentation on product quality, safety, and efficacy.
Estimated Timeline for Registration: The registration process can take approximately 6 to 12 months, depending on the complexity of the application.
Import Tariff/Duty for HS 30049099: Pharmaceutical imports may be subject to tariffs; importers should consult the latest tariff schedules from Peruvian customs authorities.
Belgium:
Regulatory Authority: Federal Agency for Medicines and Health Products (FAMHP).
Import Registration Process: Importers must obtain a marketing authorization from FAMHP, ensuring compliance with European Medicines Agency (EMA) standards.
Estimated Timeline for Registration: The process typically takes 7 to 12 months, depending on the completeness of the dossier and any additional information requests.
Import Tariff/Duty for HS 30049099: As an EU member, Belgium generally applies a 0% tariff on pharmaceutical products under this HS code, but importers should verify current rates.
Import Registration Process: Importers must register Sunitinib in the Australian Register of Therapeutic Goods (ARTG) and comply with TGA regulations.
Estimated Timeline for Registration: The registration process can take 12 to 18 months, depending on the quality of the submission and any additional data requirements.
Import Tariff/Duty for HS 30049099: Pharmaceutical products under this HS code are typically duty-free in Australia, but importers should confirm with the Australian Border Force.
TransData Nexus Research · Government and regulatory sourcesMar 2026
Tender-Based Purchasing: Many governments and large healthcare providers use tender systems to procure medicines, aiming for cost-effectiveness and supply security. This approach can lead to bulk purchasing and stable demand for Sunitinib.
With 188 buyers across 76 countries, the global market for Sunitinib reflects a broad and sustained demand, influenced by healthcare policies, disease burden, and procurement strategies.
TransData Nexus Research · Government and regulatory sourcesMar 2026
Analysis Methodology
1.Buyer Identification: 188 global importers of Sunitinib identified from consignee fields in DGFT shipping bill records.
2.Import Value Analysis: Total import value aggregated from 607 individual shipping bill records. Values are FOB in USD.
3.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation.
4.Geographic Distribution: Buyer imports distributed across 76 destination countries with market share per buyer calculated from capped values.
